Company Overview and News

70
March To Freedom Fund: July Update

13h seekingalpha - 1
The March to Freedom Fund, which will provide the dividends that pay my wife's and my expenses in retirement, has spent much of the last year or so trailing the S&P 500 (SPY). That is something that I am fine with for two reasons: 1) In previous years we’ve outperformed the index in years that it suffered a loss (for example, 5.4% total return for our portfolio, -2.2% total return for the S&P 500 in 2015).
SOJA LMT GIS XOM TWX OPRF CVS ABT NKE HON SYK AAPL ABBV ABT VTR HON SO O MA TWC CMI TGT V AFL PEP CVX DG MSFT SBUX ABBV QCOM

0
167-Year-Old MassMutual Adds New Online Startup With Quilt Deal - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AFL 8686 AFSD

3
Insurance ETFs Looking Good Post Q2 Earnings

2018-08-08 zacks
The insurance industry has performed well this reporting cycle with robust earnings from leading players. Prominent players such as MetLife (MET - Free Report) , Chubb Corp (CB - Free Report) and Allstate (ALL - Free Report) surpassed earnings and revenue estimates. While American International (AIG - Free Report) and Travelers (TRV - Free Report) missed earnings estimates, Aflac (AFL - Free Report) lagged revenue estimates.
IAK PRU ALL AFL KIE PRH PFK MET CB PRU PJH

0
Why Aflac (AFL) is a Great Dividend Stock

2018-08-07 zacks
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
AFL AMT NHI BCRX GTLS

0
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

2018-08-06 zacks
Designed to provide broad exposure to the Large Cap Blend segment of the US equity market, the First Trust Capital Strength ETF (FTCS - Free Report) is a passively managed exchange traded fund launched on 07/06/2006.
IVV AFL 8686 IVV VLO AFSD BGSF FUN ROK

0
AFL / AFLAC, Inc. 10-Q (Quarterly Report)

2018-08-03 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AFL

9
American International (AIG) Q2 Earnings Miss Estimates

2018-08-03 zacks
American International Group Inc. (AIG - Free Report) reported second-quarter 2018 operating earnings of $1.05 per share, missing the Zacks Consensus Estimate by 11.8%. Also, in the year-ago quarter, the company’s bottom line came in at $1.53.
TMK AVF TMK AIG AFL 8686 AFSD GNW 8685

7
The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Citigroup, Petrobras and Aflac

2018-08-03 zacks
Chicago, IL –August 3, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple (AAPL - Free Report) , Procter & Gamble (PG - Free Report) , Citigroup (C - Free Report) , Petrobras (PBR - Free Report) and Aflac (AFL - Free Report) .
C AFL CY AAPL HEAR

12
Top Research Reports for Apple, Procter & Gamble & Citigroup

2018-08-02 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG) and Citigroup (C). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
FISV BRK.A C AFL DRE XOM AAPL IPGP UTX FSLR

8
Lincoln's (LNC) Q2 Earnings Miss Estimates, Increase Y/Y

2018-08-02 zacks
Lincoln National Corporation’s (LNC - Free Report) second-quarter 2018 earnings of $2.02 per share missed the Zacks Consensus Estimate by 3.8%. However, the bottom line improved about 9.2% year over year, mainly led by solid performances across all segments, annuity sales and the recent acquisition of Liberty.
TMK LNC AFL 8686 ENR AFSD GNW TMK

4
Unum Group (UNM) Q2 Earnings Beat Estimates, Revenues Miss

2018-08-01 zacks
Unum Group’s (UNM - Free Report) second-quarter 2018 operating net income of $1.30 per share beat the Zacks Consensus Estimate by 2.4%. Moreover, the bottom line improved 20.3% year over year on higher premiums and a stable benefits experience. Moreover, lower tax rate provided an additional boost to the metric.
UNM EIG BRK.A TMK AFL 8686 AFSD TMK

0
Aflac's Q2 2018: A SWAN Stock

2018-07-28 seekingalpha
Net income grew by 16% to $832 million in Q2 and by 18.8% to $1.55 billion on a year-to-date basis.
AFL

0
Aflac's (AFL) CEO Daniel Amos on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Welcome to the Aflac Second Quarter Earnings Conference Call. Your lines have been placed on listen-only until the question-and-answer session. Please be advised today's conference is being recorded.
AFL MS

3
Aflac (AFL) Q2 Earnings Surpass Estimates, Revenues Miss

2018-07-27 zacks - 1
Aflac Inc.’s (AFL - Free Report) second-quarter 2018 earnings of $1.07 per share surpassed the Zacks Consensus Estimate by 9.2% and increased 15.2% year over year. Results buoyed up on overall favorable pretax margins and a lower effective tax rate as a result of tax reform.
EA AFL PGR NVR 8686 AFSD MTG TRN RLI

0
AFL / AFLAC, Inc. 8-K (Current Report)

2018-07-27 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AFL

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 001055102